Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma

Ying Han(Fujian University of Traditional Chinese Medicine), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yong-Wen Song(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaohui He(Chinese Academy of Medical Sciences & Peking Union Medical College), Shengyu Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Changgong Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Liqiang Zhou(Henan University of Science and Technology)
The Oncologist
April 5, 2019
10.1634/theoncologist.2018-0361
Cited by 42

Related Papers

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
|The Lancet Respiratory Medicine|2022|235